Changes in the Rate of Leucine-Rich Glioma-Inactivated 1 Seropositivity During the COVID-19 Lockdown

JAMA Neurol. 2023 Apr 1;80(4):419-420. doi: 10.1001/jamaneurol.2022.5346.
No abstract available

Plain language summary

This case-control study investigates the positivity rates of the most prevalent neuroglial surface antibodies during the COVID-19 pandemic.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • COVID-19*
  • Communicable Disease Control
  • Glioma*
  • Humans
  • Leucine
  • Proteins

Substances

  • Leucine
  • Proteins